Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers.

Int J Mol Sci · 2023 · PMC9862040 · PMID 36674809

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

quite significantno p-value reported

Surprisingly, the rate of grade 3–4 adverse events was quite significant, reaching 48%, which might become a serious challenge in this vulnerable patient population [ 122 ].

also in 5,695 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.